Author: Egetis Therapeutics

Posted Date:

June 10, 2026

Egetis Therapeutics Announces National Re-Airing of Behind the Mystery Episode on Lifetime Spotlighting MCT8 Deficiency

Egetis Therapeutics

June 10, 2026
Egetis to Present Healthcare Resource Drivers and Cost in MCT8 Deficiency at ISPOR 2026

Egetis Therapeutics

May 19, 2026
Egetis Therapeutics to Participate in Leading International Medical Conferences in 2026

Egetis Therapeutics

May 7, 2026
Egetis Announces Grant of Patent for MCT8 Deficiency Composition in The U.S.

Egetis Therapeutics

May 5, 2026
Egetis Therapeutics to Participate in Pediatric Endocrine Society Annual Meeting 2026

Egetis Therapeutics

April 30, 2026
Egetis Appoints Tiago Nunes as Chief Medical Officer

Egetis Therapeutics

April 9, 2026
Egetis Announces FDA Acceptance and Priority Review of NDA for Emcitate(R) (tiratricol) for MCT8 Deficiency

Egetis Therapeutics

March 27, 2026
Egetis Receives Notice of Allowance for MCT8 Deficiency Composition Patent in the U.S.

Egetis Therapeutics

March 9, 2026
Egetis Therapeutics Launches Educational Websites on MCT8 Deficiency for Physicians and Caregivers

Egetis Therapeutics

March 2, 2026